OptiBiotix Health plc – Cesarean Birth and Risk of Obesity

A study by Harvard University has showed that children born by c-section had a 64 per cent greater chance of becoming obese when compared with natural born siblings and babies born by caesarean section are 15 per cent more likely to become obese as children compared to those born naturally.

“Our findings particularly those that show a dramatic difference in obesity risk between those born via caesarean and their siblings born through vaginal delivery provide very compelling evidence that the association between cesarean birth and childhood obesity is real.

“That’s because, in the case of siblings, many of the factors that could potentially be playing a role in obesity risk, including genetics, would be largely the same for each sibling–except for the type of delivery.” – Dr Jorge Chavarro, associate Professor of Nutrition and Epidemiology at Harvard Chan School of Medicine

The study has been published online by JAMA Pediatrics.

Stephen OHara, OptiBiotix Health Plc CEO said: “This report identifies that children born by caesarean section had a 15 per cent greater chance of becoming obese when compared with natural born siblings and this may be related to differences in the gut bacteria at birth. This is one of a growing number of scientific publications evidencing the role of the microbiome in human disease. OptiBiotix has developed microbiome modulators which can change the numbers of specific microbial strains in the gut, and most important their biological activity related to a health benefit. This creates the opportunity for targeted microbiome modulation and with it the ability to prevent, manage, and treat many human diseases.”

OptiBiotix Health plc (LON:OPTI) has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really